Skip to content
2000
Volume 21, Issue 16
  • ISSN: 1389-5575
  • E-ISSN: 1875-5607

Abstract

SET protein is a multi-functional oncoprotein that is ubiquitously expressed in most tumor cells. Dysregulation of SET has been associated with many types of cancer. Due to ever-accumulating evidence of its strong correlation with both poor prognosis and drug resistance, the targeting of SET is starting to be explored. SET is currently regarded as a potential target for cancer therapy, and several inhibitors are being developed for clinical trials. In this review, the physiological and pathological functions of SET, as well as its antagonists, will be discussed along with the prospects and challenges involved with translating SET inhibitors into bona fide therapeutic options.

Loading

Article metrics loading...

/content/journals/mrmc/10.2174/1389557521666210114163318
2021-10-01
2024-11-02
Loading full text...

Full text loading...

/content/journals/mrmc/10.2174/1389557521666210114163318
Loading
  • Article Type: Review Article
Keyword(s): cancer; dysregulation; inhibitors; oncoprotein; prognosis; resistance; SET
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test